William Blair Issues Pessimistic Outlook for IQVIA Earnings

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Investment analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of IQVIA in a note issued to investors on Thursday, February 6th. William Blair analyst M. Smock now expects that the medical research company will earn $2.35 per share for the quarter, down from their prior estimate of $2.37. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for IQVIA's current full-year earnings is $10.81 per share.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%.

Other equities research analysts also recently issued research reports about the company. Truist Financial restated a "buy" rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target on the stock. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Leerink Partners restated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Bank of America cut their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $251.67.

IQVIA Stock Performance

IQV traded down $1.64 during midday trading on Monday, reaching $196.18. The company's stock had a trading volume of 905,564 shares, compared to its average volume of 1,394,378. The stock has a market cap of $35.61 billion, a P/E ratio of 26.16, a PEG ratio of 2.25 and a beta of 1.48. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. The company has a fifty day simple moving average of $200.66 and a 200 day simple moving average of $218.67.

Insider Buying and Selling

In related news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of IQVIA

A number of large investors have recently bought and sold shares of IQV. Norges Bank acquired a new stake in IQVIA during the 4th quarter worth about $336,041,000. Raymond James Financial Inc. acquired a new stake in IQVIA during the 4th quarter worth about $236,120,000. American Century Companies Inc. grew its holdings in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after acquiring an additional 905,960 shares during the period. Invesco Ltd. grew its holdings in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after acquiring an additional 902,226 shares during the period. Finally, FMR LLC grew its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.